Who Paid My Doc
Noshir Dacosta
Hematology & Oncology Smithtown, NY Medical Doctor
NPI 1154300622 CMS profile 6405
48 Route 25A Ste 209, Smithtown, NY 11787
General payments
$4,258
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,000
Through program year 2025, Noshir Dacosta of Smithtown, NY is reported in the CMS Open Payments database as having received $4,258 across 25 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 57th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $74 | 3 | |
| 2023 | General | $100 | 1 | |
| 2022 | General | $19 | 1 | |
| 2021 | General | $64 | 5 | |
| 2020 | General | $1,972 | 7 | |
| 2019 | General | $2,031 | 8 |
Beside peers
- Noshir Dacosta
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Noshir Dacosta were reported at $74. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Noshir Dacosta | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,031 | $529 | $121–$2,516 | $163 |
| 2020 | $1,972 | $339 | $82–$2,213 | $114 |
| 2021 | $64 | $263 | $49–$1,965 | $132 |
| 2022 | $19 | $416 | $103–$2,395 | $149 |
| 2023 | $100 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $74 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 59 drugsPart D claims
2,420
Drug cost
$11,353,575
Branded share of claims
69.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Imbruvica Ibrutinib | Brand | 75 | $1,325,659 | |
| Somatuline Depot Lanreotide Acetate | Brand | 93 | $836,103 | |
| Aranesp Darbepoetin Alfa In Polysorbat | Brand | 250 | $833,512 | |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | Brand | 76 | $750,741 | |
| Keytruda Pembrolizumab | Brand | 54 | $609,591 | |
| Revlimid Lenalidomide | Brand | 35 | $534,179 | |
| Xtandi Enzalutamide | Brand | 36 | $498,047 | |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | Brand | 36 | $419,847 | |
| Kisqali Ribociclib Succinate | Brand | 29 | $384,342 | |
| Calquence Acalabrutinib Maleate | Brand | 23 | $356,199 |
The 10 drugs with the highest cost, of 59 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 285 billing codesPaid by Medicare
$2,482,807
Medicare patients
1,671
Services billed
145,112
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 54% | |
| Cancer | 48% | |
| Ischemic heart disease | 43% | |
| Diabetes | 36% | |
| Chronic kidney disease | 35% | |
| Osteoporosis | 26% | |
| Atrial fibrillation | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 19 | 7,100 | $310,700 |
| Injection, denosumab, 1 mg J0897 | Office | 36 | 5,160 | $105,580 |
| Injection, ferric carboxymaltose, 1 mg J1439 | Office | 47 | 36,750 | $32,149 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 | Office | 15 | 40 | $21,190 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 17 | 8,700 | $17,932 |
| Vaccine for influenza for injection into muscle 90662 | Office | 31 | 31 | $2,527 |
| Injection, iron sucrose, 1 mg J1756 | Office | 20 | 6,000 | $1,025 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 81 | 1,821 | $161 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 | Office | 45 | 85 | $88 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 52 | 96 | $61 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
25 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in New York
Michael Schuster
Hematology & Oncology · New York, NY
Charles Sawyers
Hematology & Oncology · New York, NY
Manuel Hidalgo-Medina
Hematology & Oncology · New York, NY
Francis Arena
Hematology & Oncology · Lake Success, NY
Sanjeev Jain
Hematology & Oncology · East Patchogue, NY
Ross Levine
Hematology & Oncology · New York, NY
Related records
Hematology & Oncology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.